Tag: novartis

Another Win for Novartis

28th June, 2023 - 8:28 am Categories: Legal Issues Patent Act

Introduction It has been contended by the Pharma major that it is the patentee of the two tablets under the brand ‘Vymada’ in India. The plaintiff, Novartis was represented through advocate Mamta Jha and the primary bone of contention was to obtain a restraining order against the defendants. Moreover, the amount of time and efforts … Continue reading Another Win for Novartis

Read more »

The Dichotomy of IPR Protection and Social Welfare- An Analysis of the Indian Patents Act with respect to the Pharmaceutical Industry

23rd January, 2020 - 10:35 am Categories: bLAWgathon

Introduction Intellectual Property Rights, in the simplest of terms, refer to rights over creation of the mind. In a world where knowledge economies are on the rise, IPR has become increasingly significant. Intellectual Property Rights entail several rights within its ambit- copyright, patent, geographical indication etc. In this article, we deal only with one form of … Continue reading The Dichotomy of IPR Protection and Social Welfare- An Analysis of the Indian Patents Act with respect to the Pharmaceutical Industry

Read more »

To Patent, Or Not To Patent, That Is The Question

11th December, 2019 - 4:12 am Categories: Patents

The granting of secondary use patents in the pharmaceutical industry has become more prominent after the negotiations of the TRIPS Agreement in 1995. More and more secondary use patents have been granted, especially in developed countries. But, on the flip side, some firms tend to take advantage of secondary use patents in order to extend … Continue reading To Patent, Or Not To Patent, That Is The Question

Read more »

Patentee Rights During Pendency Of Post-Grant Opposition

20th May, 2019 - 4:32 am Categories: Legal Issues

Issues: In the case of Novartis AG & ANR v Natco Pharma Ltd, Swiss Pharma major Novartis has been granted patent for novel and inventive compound “Certinib” for treatment of non-small cell lung cancer. The suit patent was filed claiming priority since 2007, and was granted on 28th September, 2015. Novartis came across NOXALK (Natco … Continue reading Patentee Rights During Pendency Of Post-Grant Opposition

Read more »

News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”

22nd December, 2014 - 6:27 am Categories: India IP Litigation IP Practice in India News & Updates patent infringement Patents pharma

In a latest update, Novartis has sued Cipla for infringing its patents on “Onbrez” (Indacaterol) after Cipla lunched its generic version for Indacaterol in October claiming “urgent unmet need” for the drug in India. Earlier, as we have reported here, Cipla approached Govt. of India to exercise its statutory powers to revoke the five patents … Continue reading News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”

Read more »

CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government

17th December, 2014 - 8:25 am Categories: India IP Litigation IP Practice in India News & Updates Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

As reported in TOI, the Indian Government has found very little merit in Cipla’s plea for waiver and cancellation of Patent rights for chronic obstructive pulmonary disease (COPD) drug over which Novartis has exclusive rights. We have reported on Cipla’s plea here. Background: Cipla, previously approached the Department of Industrial Policy and Promotion (DIPP) to … Continue reading CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government

Read more »

Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents

1st November, 2014 - 5:27 pm Categories: India IP Litigation IP Practice in India News & Updates Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

It has been recently reported in Economic times that Cipla has filed representation with the government (Department of Industrial Policy & Promotion) seeking revocation of five patents of Novartis on indacaterol, a respiratory drug for the treatment of chronic obstructive pulmonary disease (COPD) and marketed as Onbrez by Novartis. The central government, under section 66 … Continue reading Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents

Read more »

The Glivec saga in India is finally over

9th April, 2013 - 9:38 am Categories: IP Practice in India News & Updates

As it has been widely covered by media in and outside India, it is no new news to pharmaceutical and patent fraternity that Novartis has lost about 7 year long legal battle to secure a patent protection for its invention on beta crystalline form of imatinib mesylate in India. A 112 page long Supreme Court judgement … Continue reading The Glivec saga in India is finally over

Read more »

Actavis and Novartis

15th April, 2010 - 3:52 am Categories: Patent Litigation Pharma/Biotech Patent Litigations

ACTAVIS’ “EXPECTATION OF SUCCESS” AFFIRMED ACTAVIS UK vs NOVARTIS AG The High Court, Court of Appeal has recently upheld a decision on Appeal from the High Court, Patents Court, that the Novartis’s European Patent (UK) 0948320, a sustained release formulation of Fluvastatin (a Cholesterol lowering drug), is invalid on the ground of obviousness. Earlier in … Continue reading Actavis and Novartis

Read more »

Categories

Archives